Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares Issued Shares Outstanding Shares Outstanding

Ratios

Enliven Therapeutics (ELVN) Preferred Shares Issued (2019 - 2020)

Enliven Therapeutics has reported Preferred Shares Issued over the past 2 years, most recently at $17.2 million for Q1 2020.

Quarterly results put Preferred Shares Issued at $17.2 million for Q1 2020, down 60.96% from a year ago — trailing twelve months through Dec 2020 was $17.2 million (down 62.37% YoY), and the annual figure for FY2020 was $17.2 million, down 62.37%.
Preferred Shares Issued reached $17.2 million in Q1 2020 per ELVN's latest filing, up from $1.6 million in the prior quarter.
Across five years, Preferred Shares Issued topped out at $43.9 million in Q1 2019 and bottomed at $1.6 million in Q2 2019.